Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pain Control With Total Knee Replacement (L12-078)

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Texas Tech University Health Sciences Center Identifier:
First received: September 4, 2012
Last updated: May 21, 2014
Last verified: May 2014

The purpose of this project is to study the effects of gabapentin on pain control in the perioperative and post-operative period of total knee arthroplasty.

Condition Intervention Phase
Postoperative Pain
Drug: Gabapentin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Pain Control With Total Knee Replacement: Does Gabapentin Affect Narcotic Usage and Functional Outcome? A Randomized Controlled Trial.

Resource links provided by NLM:

Further study details as provided by Texas Tech University Health Sciences Center:

Primary Outcome Measures:
  • Patients pain assessed by the Visual Analog Scale (VAS) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    Post-operative pain assessed by a call daily from the study coordinator daily asking the VAS for 2 weeks

Secondary Outcome Measures:
  • Functional Outcome [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    Patients functional outcome will be assessed by a daily home call to the patient from the study coordinator, and home physical therapy documents

Estimated Enrollment: 72
Study Start Date: September 2012
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Gabapentin
Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
Drug: Gabapentin
Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
Other Names:
  • Fanatrex
  • Gabarone
  • Gralise
  • Horizant
  • Neurontin
Placebo Comparator: Placebo
Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
Drug: Gabapentin
Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
Other Names:
  • Fanatrex
  • Gabarone
  • Gralise
  • Horizant
  • Neurontin

Detailed Description:

Being able to understand and better control pain in patients undergoing total knee arthroplasty will help in many different areas of medicine. Gabapentin is one pain control modality that has been used by many different orthopaedic surgeons with excellent retrospective results. Gabapentin, however, has never been studied, to the investigators knowledge, in a prospective randomized fashion in the United States for total knee arthroplasty. This study will be the first of its kind to truly compare the effects of gabapentin, a drug that has been proven safe in many other areas of medicine, with placebo for total knee arthroplasty by analyzing post-operative narcotic usage, function and sleep quality.


Ages Eligible for Study:   25 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • • Age > 25 years old

    • Primary osteoarthritis of the knee
    • Must be undergoing unilateral total knee arthroplasty
    • Anesthesia assesment score I, II, or III

Exclusion Criteria:

  • Severe joint malalignment (defined as varus/valgus angle > 20 deg)

    • Use of gabapentin pre-operatively
    • History of chronic pain (currently under treatment)
    • History of substance abuse
    • Impaired kidney function (defined as creatinine > 1.5)
    • Epilepsy (currently on medication for treatment)
    • Known allergy to Gabapentin
    • Known history of depression or suicidal thoughts and behaviors
    • Anyone who is not a candidate for general anesthesia or any other portion of the investigator's standard of care.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01680549

United States, Texas
TTUHSC Orthopaedic Surgery MS 9436
Lubbock, Texas, United States, 79430
Sponsors and Collaborators
Texas Tech University Health Sciences Center
Principal Investigator: George W Brindley, MD TTUHSC dept. Orthopaedic Surgery
  More Information

No publications provided

Responsible Party: Texas Tech University Health Sciences Center Identifier: NCT01680549     History of Changes
Other Study ID Numbers: L12-078
Study First Received: September 4, 2012
Last Updated: May 21, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Anti-Anxiety Agents
Anti-Dyskinesia Agents
Antimanic Agents
Antiparkinson Agents
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Tranquilizing Agents processed this record on February 27, 2015